$1.10
-0.01 (-0.90%)
Open$1.11
Previous Close$1.11
Day High$1.12
Day Low$1.08
52W High$2.88
52W Low$0.77
Volume—
Avg Volume202.5K
Market Cap33.95M
P/E Ratio—
EPS$-1.92
SectorBiotechnology
Analyst Ratings
Strong Buy
10 analysts
Price Target
+194.5% upside
Current
$1.10
$1.10
Target
$3.24
$3.24
$1.82
$3.24 avg
$4.40
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 31.1K | 180.5K | 15.18M |
| Net Income | -85,106,160 | -444,032,139 | 1.21M |
| Profit Margin | -279,263.6% | -265,300.5% | 8.0% |
| EBITDA | -91,487,720 | -503,845,414 | 1.98M |
| Free Cash Flow | — | — | 1.07M |
| Rev Growth | -82.8% | -82.8% | +1.7% |
| Debt/Equity | — | — | 0.33 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $251.64 | -1.05% | 118.2 | 429.58B |
| AMGN | Amgen Inc | $362.12 | +0.44% | 24.8 | 193.10B |
| GILD | Gilead Sciences Inc | $126.34 | +0.01% | 17.1 | 157.21B |
| VRTX | Vertex Pharmaceuticals Inc | $496.73 | -0.58% | 28.1 | 121.87B |
| REGN | Regeneron Pharmaceuticals | $623.54 | -1.31% | 15.0 | 66.35B |
| ALNY | Alnylam Pharmaceuticals Inc | $301.03 | +2.56% | 69.3 | 39.97B |